Noah Federman
YOU?
Author Swipe
View article: Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma
Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma Open
Importance Standard preoperative radiotherapy (RT) for high-risk soft tissue sarcoma (STS) is delivered over 5 weeks, which can be a logistical challenge for patients. Objective To evaluate the long-term toxic effects and clinical outcomes…
View article: Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial Open
In the phase III placebo-controlled DeFi trial (ClinicalTrials.gov identifier: NCT03785964 ) primary analysis, nirogacestat showed significant improvement versus placebo in progression-free survival (PFS), objective response rate (ORR), an…
View article: Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance
Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance Open
Leucine-rich repeat containing 15 (LRRC15) has emerged as an attractive biomarker and target for cancer therapy. Transforming growth factor-β (TGFβ) induces the expression of this plasma membrane protein specifically in aggressive and trea…
View article: Neoadjuvant Chemotherapy Is Associated With Reduced Amputation Risk in Synovial Sarcoma of the Lower Extremity
Neoadjuvant Chemotherapy Is Associated With Reduced Amputation Risk in Synovial Sarcoma of the Lower Extremity Open
Background and Objectives The combination of radiation and surgical resection represents the current standard of care for primary synovial sarcoma (SS). However, controversy remains regarding the role of chemotherapy. We sought to evaluate…
View article: Noninvasive Assessment of Protease Activity in Osteosarcoma via Click Chemistry‐Mediated Enrichment of Extracellular Vesicles
Noninvasive Assessment of Protease Activity in Osteosarcoma via Click Chemistry‐Mediated Enrichment of Extracellular Vesicles Open
Osteosarcoma (OS), the most common bone cancer in children, is characterized by aggressive tumors and subclinical metastasis. Metastasis significantly impacts OS patient survival rate, highlighting the need for frequent assessment of disea…
View article: 216 UCLA’s Clinical and Translational Science Institute (CTSI) and the California Institute for Regenerative Medicine (CIRM) Trainee Collaborative Efforts
216 UCLA’s Clinical and Translational Science Institute (CTSI) and the California Institute for Regenerative Medicine (CIRM) Trainee Collaborative Efforts Open
Objectives/Goals: By synergizing our efforts, we believe this to be a fruitful collaboration for UCLA Clinical and Translational Science Institute (CTSI) and California Institute for Regenerative Medicine (CIRM). With multiple levels to st…
View article: 160 Empowering future healthcare leaders and clinical researchers across a decade: UCLA’s Clinical and Translational Science Institute – Research Associates Program
160 Empowering future healthcare leaders and clinical researchers across a decade: UCLA’s Clinical and Translational Science Institute – Research Associates Program Open
Objectives/Goals: To assess the impact of UCLA’s Clinical and Translational Science Institute Research Associates Program (CTSI-RAP), a student-led undergraduate clinical research initiative, on current members’ career interests and develo…
View article: 8 A decade of excellence and impact: The UCLA Clinical And Translational Science Institute – Research Associates Program (CTSI-RAP)
8 A decade of excellence and impact: The UCLA Clinical And Translational Science Institute – Research Associates Program (CTSI-RAP) Open
Objectives/Goals: The impact of the program on alumni students was measured in a 2023 survey, which assessed key factors and student perspectives on motivation to apply/remain in the program, their engagement activities, how they used the …
View article: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors Open
Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with efficacy in children with TRK fusion tumors. We evaluated patient outcomes after elective discontinuation of larotrectinib in the absence of disease progr…
View article: 160 Empowering future healthcare leaders and clinical researchers across a decade: UCLA’s Clinical and Translational Science Institute – Research Associates Program – CORRIGENDUM
160 Empowering future healthcare leaders and clinical researchers across a decade: UCLA’s Clinical and Translational Science Institute – Research Associates Program – CORRIGENDUM Open
[This corrects the article DOI: 10.1017/cts.2024.818.].
View article: Evaluating the implementation and impact of a volunteer navigation oncology support programme: study protocol for a pragmatic, real-world hybrid type 2 study
Evaluating the implementation and impact of a volunteer navigation oncology support programme: study protocol for a pragmatic, real-world hybrid type 2 study Open
Introduction Patient navigation is recommended by accrediting bodies such as the Commission on Cancer and is a key element in payment reform demonstration projects, due to the established benefits in reducing barriers to healthcare, improv…
View article: The landscape of drug sensitivity and resistance in sarcoma
The landscape of drug sensitivity and resistance in sarcoma Open
Sarcomas are rare malignancies with over 100 distinct histological subtypes. Their rarity and heterogeneity pose significant challenges to identifying effective therapies, and approved regimens show varied responses. Novel, personalized ap…
View article: Entinostat as a combinatorial therapeutic for rhabdomyosarcoma
Entinostat as a combinatorial therapeutic for rhabdomyosarcoma Open
Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. For the alveolar subtype (ARMS), the presence of the PAX3::FOXO1 fusion gene and/or metastases are strong predictors of poor outcome. Metastatic PAX3::FOXO1 + ARMS of…
View article: Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma Open
PURPOSE Ewing Sarcoma (ES), a rare cancer with a pathognomonic translocation resulting in the Ewing sarcoma gene (EWS)::FLI1 oncoprotein, has a poor prognosis in the relapsed/refractory (R/R) setting. Tokalas (TK)216 was designed to bind E…
View article: Clinical characteristics and treatment patterns of patients with <i>NTRK</i> fusion–positive solid tumors: A multisite cohort study at US academic cancer centers
Clinical characteristics and treatment patterns of patients with <i>NTRK</i> fusion–positive solid tumors: A multisite cohort study at US academic cancer centers Open
This study reports on contemporary real-world NTRK testing patterns and use of TRKis in solid tumors, including time between NTRK testing and initiation of TRKi therapy and duration of TRKi therapy.
View article: Proceedings of the Think Tank for Osteosarcoma Medical Advisory Board
Proceedings of the Think Tank for Osteosarcoma Medical Advisory Board Open
A "Think Tank for Osteosarcoma" medical advisory board meeting was held in Santa Monica, CA, USA on February 2-3, 2024. The goal was to develop a strategic approach to prevent recurrence of osteosarcoma. Osteosarcoma metabolism and the gen…
View article: Maternal Exposure to Heavy Metals From Industrial Sources During Pregnancy and Childhood Cancer Risk in California
Maternal Exposure to Heavy Metals From Industrial Sources During Pregnancy and Childhood Cancer Risk in California Open
Objective The study investigated maternal exposure to heavy metals from industrial sources during pregnancy as potential risk factors for childhood cancer. Methods Cases ages 0–19 were identified from California Cancer Registry. Controls (…
View article: Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study
Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study Open
Introduction Nirogacestat is a targeted gamma secretase inhibitor approved in the United States for adults with progressing desmoid tumors. In the phase 3 DeFi study (NCT03785964) of nirogacestat, ovarian toxicity (OT) was identified as a …
View article: 120 Impact of Undergraduate Clinical Research Experience: Highlighting the UCLA Clinical and Translational Science Institute Research Associates Program (CTSI-RAP)
120 Impact of Undergraduate Clinical Research Experience: Highlighting the UCLA Clinical and Translational Science Institute Research Associates Program (CTSI-RAP) Open
OBJECTIVES/GOALS: CTSI-RAP is a professional development program that provides undergraduate students with clinical research exposure and training. Students support UCLA research faculty by assisting with all aspects of the research proces…
View article: 136P Efficacy and safety of larotrectinib (laro) as first-line treatment for paediatric (paed) patients (pts) with TRK fusion cancer
136P Efficacy and safety of larotrectinib (laro) as first-line treatment for paediatric (paed) patients (pts) with TRK fusion cancer Open
Laro is the first-in-class, highly selective, central nervous system (CNS)-active TRK inhibitor approved for tumour-agnostic use in pts with TRK fusion cancer based on a robust and durable overall response rate (ORR) in both adult and paed…
View article: Editorial: Celebrating the 200th mendel’s anniversary: gene-targeted diagnostics and therapies for cancer
Editorial: Celebrating the 200th mendel’s anniversary: gene-targeted diagnostics and therapies for cancer Open
EDITORIAL article Front. Mol. Med, 27 February 2024Sec. Molecular Medicine and Cancer Treatment Volume 4 - 2024 | https://doi.org/10.3389/fmmed.2024.1366963
View article: 120 Impact of Undergraduate Clinical Research Experience: Highlighting the UCLA Clinical and Translational Science Institute Research Associates Program (CTSI-RAP) – CORRIGENDUM
120 Impact of Undergraduate Clinical Research Experience: Highlighting the UCLA Clinical and Translational Science Institute Research Associates Program (CTSI-RAP) – CORRIGENDUM Open
[This corrects the article DOI: 10.1017/cts.2024.117.].
View article: 120 Impact of Undergraduate Clinical Research Experience: Highlighting the UCLA Clinical and Translational Science Institute Research Associates Program (CTSI-RAP) – CORRIGENDUM
120 Impact of Undergraduate Clinical Research Experience: Highlighting the UCLA Clinical and Translational Science Institute Research Associates Program (CTSI-RAP) – CORRIGENDUM Open
[This corrects the article DOI: 10.1017/cts.2024.117.].
View article: Exploring Barriers to Pediatric Cancer Clinical Trials: The Role of a Networked, Just-in-Time Study Program
Exploring Barriers to Pediatric Cancer Clinical Trials: The Role of a Networked, Just-in-Time Study Program Open
The Research to Accelerate Cures and Equity (RACE) for Children Act mandates that newly developed targeted oncology drugs be tested in children when molecular targets are relevant to pediatric cancers. In its first year, the RACE for Child…